Prevalence of large vessel vasculitis in ANCA-associated vasculitis: a retrospective cohort study

Yann Coattrenec1 · Yannick D. Muller2 · David Spoerl1 · Johannes A. Lobrinus3 · Jörg D. Seebach1

Received: 2 June 2021 / Accepted: 11 September 2021 / Published online: 24 September 2021
© The Author(s) 2021

Abstract
ANCA-associated vasculitis (AAV) in general involves small blood vessels and includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), and microscopic polyangiitis (MPA). Although reported in a few studies, the prevalence of large vessel vasculitis (LVV) in patients with AAV remains to be further explored. The goal of the present study was to assess the prevalence of LVV in a cohort of patients with AAV and to characterize this population. We conducted a ten-year retrospective study of a single-center cohort of AAV, including 101 patients with GPA (n = 58), EGPA (n = 28), MPA (n = 15), and compared the groups with or without associated LVV. LVV was diagnosed in five patients, two with aortitis and three with temporal arteritis, corresponding to a total prevalence of 5.0% [95% CI 1.6–11.2%]. This value was significantly higher than the estimated prevalence of LVV in the normal Swiss population (OR 234.9 95% CI 91.18–605.2, p < 0.001). All five patients had GPA, whereas no cases with EGPA or MPA were identified. Anti-PR3 antibodies were detected in four out of five patients, anti-MPO in one patient. Since LVV can occur in a significant proportion of patients with GPA, evaluation for LVV may be considered systematically in the diagnostic workup of AAV.

Keywords ANCA-associated vasculitis · Antineutrophil cytoplasmic antibodies · Large vessel vasculitis · Temporal arteritis · Aortitis · Granulomatosis with polyangiitis · Eosinophilic granulomatosis with polyangiitis · Microscopic polyangiitis

Introduction
According to the 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are small vessels vasculitis, encompassing granulomatosis with polyangiitis (GPA, previously known as Wegener’s granulomatosis), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA, previously known as Churg–Strauss disease), and single-organ AAV (like renal-limited AAV) [1]. Diseases with large vessel vasculitis (LVV) include Takayasu arteritis and giant cell arteritis (GCA, Horton’s disease), the first condition being much rarer than the latter.

The association between AAV and LVV is not clearly established in the literature. Some authors refer to polyangiitis overlap syndromes, a type of systemic vasculitis that represents several diagnostic categories [2, 3]. Indeed, there are several reports of patients diagnosed with both GCA and GPA [2–13], MPA [7, 14–18], or EGPA [19]. A retrospective cohort of the Mayo Clinic identified five cases of temporal arteritis among 345 patients with GPA [4]. Another study found seven patients with necrotizing vasculitis among 120 temporal artery biopsies with GCA, including one case of GPA and three cases of MPA [7]. On the other hand, case series reports the presence of ANCA in up to 30% of GCA patients, mostly without -PR3/-MPO specificity and without fulfilling the criteria for AAV [20, 21]. In the present study, we assessed the prevalence of LVV in AAV patients,
by studying a cohort of 101 patients with established GPA, MPA, and EGPA.

**Patient data collection, materials and methods**

We retrospectively selected patients from our hospital between 2006 and 2016 with the diagnosis of GPA, MPA, EGPA, and AAV based on medical records. Patients were selected between 2006 and 2016 by a diagnostic code entered in the consultation or hospital discharge reports, as well as by an internal register of our department, and a list of positive ANCA results with MPO or PR3 specificity. Only patients who fulfilled the ACR criteria for GPA and EGPA, and the Chapel Hill definition for MPA were enrolled [1, 22, 23]. For GPA, at least two of the following four criteria must be present: (1) nasal or oral inflammation, (2) abnormal chest radiographic findings, (3) abnormal urinary sediment, (4) granulomatous inflammation in the biopsy specimen. For EGPA, at least four of the following six criteria must be present: (1) asthma, (2) eosinophilia >10%, (3) mono or poly neuropathy (4) non fixed pulmonary infiltrate, (5) paranasal sinus abnormality, (6) extravascular eosinophils. For MPA, Chapel Hill definition was used: necrotizing vasculitis, with few or no immune deposits, predominantly affecting small vessels (i.e., capillaries, venules, or arterioles) with necrotizing glomerulonephritis or pulmonary capillaritis without granuloma formation. Patients without the above mentioned criteria or insufficient data were excluded from the study. We identified a fourth group, single-organ AAV with histologic evidence of small vessel vasculitis and specific ANCA (-PR3 or -MPO), but without sufficient elements for GPA, EGPA or MPA. However, since this group of AAV is still controversial, we excluded it from the current analysis.

Temporal arteritis or aortitis were defined by the presence of inflammatory infiltrates upon histology or by comparable imaging evidence (e.g., hypercaptation on PET-CT scans). Alternatively, a typical clinic of temporal arteritis according to the ACR criteria of 1990 was also retained [24].

This study was approved by the local ethics committee (GE 2016–00,040) with a waiver for the requirement of informed consent considering the retrospective nature of the study.

Clinical and biological data were collected from centralized electronic patient files and included demographic characteristics (age, gender, year of diagnosis), laboratory results (presence and subtype of ANCA), clinical characteristics (ENT, lung, renal, cardiac, eye, joint or skin involvement), cardiovascular risk factors (hypertension, dyslipidemia, tobacco, diabetes), cardiovascular morbidity (history of myocardial infarcts, stroke, heart disease, left ventricular ejection fraction), oncologic morbidity (history of cancer), treatments (acute and maintenance), and relapse rate. ANCA were analyzed by indirect immunofluorescence on NOVA Lite ANCA ethanol and formalin slides obtained from Inova Diagnostics, San Diego, USA, according to the manufacturer’s instructions. Serum dilution started at 1/20. In case of positivity or doubtful results, an ELISA test on a DYNEX DSX processing system was used (Quanta Lite MPO/PR3 IgG ELISA, Inova Diagnostics, San Diego, USA) for confirmation, considering values < 20 units as negative. We also assessed serum creatinine, CRP, sedimentation rate at time of diagnosis. Finally, we analyzed the histological feature of biopsies if available. Most patients (89 of 108) had a follow-up of 3 years average duration, whereas 19 patients had only one visit and were lost to follow-up.

Results are reported as mean (± standard deviation) or median (± interquartile range (IQR)) for continuous variables, and in percentages (absolute numbers) for the categorical variables. The Clopper–Pearson statistical method was used to calculate the prevalence, while Mann–Whitney testing was employed to compare age between the AAV/LVV and non-LVV groups; Fisher’s exact test was used for all other analysis. Results were considered statistically significant if the p value was < 0.05.

**Results**

A total of 151 patient files and 428 positive ANCA results were identified. We selected 101 patients who fulfilled the ACR criteria or the Chapel Hill definition for GPA, EGPA, and MPA vasculitis. Seven supplementary cases had single-organ AAV, but were not further analyzed (Fig. 1).

**Demographic and clinical characteristics of patients**

The median age at the diagnosis was 59 (33–85) (Table 1) with 41% of men and 59% of women. The ANCA specificities were uniformly distributed, with 38% of perinuclear ANCA (pANCA), 32% of cytoplasmic ANCA (cANCA), 34% of MPO, and 36% of PR3. As expected, cANCA-PR3 were more common in the GPA group (62%) and pANCA-MPO were more common in the MPA group (80%). EGPA had just over 40% of ANCA positive. The most frequent clinical manifestation was pulmonary (71%), followed by ENT (58%), then renal (53%), and joint (36%) involvement.

**Prevalence of large vessel involvement**

Aortitis was found in two patients and temporal arteritis in three patients with GPA. No aortitis or temporal arteritis were identified in patients with EGPA or MPA. Therefore, LVV was found in 5 of the 101 patients analyzed,
corresponding to the hospital-based prevalence of 5.0% [95% CI 1.6–11.2%] of our overall cohort, or in 5/58 (9%) patients with GPA. These values are clearly higher compared to the prevalence of GCA in a general population close to Switzerland (Freiburg im Breisgau in Germany with 222 cases per million inhabitants [25]), resulting in odds ratio of 234.9 (95% CI 91.18–605.2, p < 0.001).

**Report of cases**

Case 1: A 66-year-old woman presented with chronic bloody nasal discharge, sero-mucous otitis and acute arthritis of the right elbow. With the onset of episcleritis and the finding of cANCA-PR3, a diagnosis of GPA was made. The patient was treated with prednisone and cyclophosphamide, subsequently replaced by mycophenolate mofetil because of hemorrhagic cystitis. The evolution was favorable. Due to weight loss of 10 kg a thoraco-abdominal CT was performed 10 years later revealing hyperdense spontaneous thickening with enhancement around the ascending and horizontal aorta. In addition pulmonary opacity of the right lower lobe was detected and a diagnosis of mononeuropathy with falling foot was made. A PET-CT showed hypermetabolism (SUV max 8.1) at the aortic arch and the ascending aorta. cANCA-PR3 were present at all times. In this context, immunosuppression by corticosteroids and mycophenolate mofetil was intensified. PET-CT scanning 18 months later showed a clear decrease in hypercaptation.

Case 2: A 52-year-old woman known for intracranial hypertension for 7 years, who was hospitalized for the investigation of headaches with tonic epileptic seizures. A brain MRI showed diffuse pachymeningitis. Due to unusual headaches located in the temporal area associated with hyperesthesia of the scalp and inflammatory syndrome, a temporal artery biopsy was performed and showed inflammatory lymphocytic infiltrate with intimal fibrosis, disappearance of the elastic lamina, and vasa vasorum granulomas. Nasal biopsy revealed mixed inflammation with rough granulomas. With MRI pansinusitis and positive cANCA-PR3, the diagnosis of GPA was made, and the patient was treated with corticosteroids and rituximab with an improvement in inflammatory syndrome and symptoms.

Case 3: A 76-year-old woman presented with progressive bilateral headaches and jaw claudication. The laboratory results revealed inflammation with a CRP of 120 mg/l and a sedimentation rate of 67 mm/h. A temporal biopsy showed a granulomatous and giant cell vasculitis (Fig. 2A). However, due to subglottic stenosis, nasal cartilage destruction, MRI pansinusitis, and persistent glomerular hematuria, a renal biopsy was performed showing segmental fibrous crescents compatible with pauciimmune extra-capillary glomerulonephritis (Fig. 2B). Perinuclear ANCs were found, specifically anti-MPO. The perinuclear ANCs remained positive over a 5-year follow-up whereas anti-MPO titers disappeared under treatment.

Case 4: A 63-year-old patient known for GPA with crusty rhinitis, CT-scan lung nodules, orbital mass and positive cANCA-PR3 was diagnosed with GCA based on ACR criteria 1990 with intermittent jaw claudication, hypersensitivity of the scalp, and transient loss of vision. A temporal biopsy was negative. However, his symptoms responded well to treatment with corticosteroids (prednisone 1 mg/kg) with normalization of erythrocyte sedimentation rate and methotrexate for a total duration of 4 years. Following the appearance of an orbital pseudotumor with diplopia, treatment with rituximab was able to induce and maintain remission.

Case 5: A 46-year-old woman, known for GPA with nasal polyps, lower limb neuropathy, and optic neuritis with granulomatous ocular infiltration, presented with aortic dissection of type A (Fig. 3A). She benefited from an emergency operation with replacement of the ascending aorta. The pathological analysis showed a granulomatous vasculitis with chronic inflammation and multiple foci of collagenous necrosis without giant cells (Fig. 3B). The evolution was satisfactory after the operation under treatment with corticosteroids.

The clinical characteristics of the five AAV patients with LVV are summarized in Table 2.
Comparison of AAV patients with and without large vessel involvement

Table 3 summarizes the differences between AAV patients with and without large vessel involvement. It is of note, that neither of these observations reached statistical significance. The age was not different with 63 ± 14.0 versus 57 ± 27.5 years (p = 0.65) (Fig. 4A), and the sex ratio was similar, with slightly more women than men in both groups. At the laboratory level, more anti-PR3 than anti-MPO (60 versus 34%) were found, a finding at the limit of statistical significance (p = 0.06). Among the five AAV patients with LVV, all having GPA, ENT manifestations seemed to be more predominant (100%), with less renal, pulmonary, neurological, and joint involvement. In the AAV group without LVV, lung manifestations (73%) were more frequent than of ENT manifestations (60%), and renal (50%) impairment (Table 3). Cardiovascular risk factors appeared to be more prevalent in the LVV group than the group without LVV, for arterial hypertension (OR 2.29 [0.45–13.26] p = 0.39), dyslipidemia (OR 1.70 [0.29–8.67] p = 0.62), and smoking (OR 6.39 [0.97–79.13] p = 0.16). Finally, there was more...
cardiac disease of any cause (hypertensive, rhythmic, valvular, ischemic, dilated, restrictive) (OR 6.37 [0.97–79.13] \( p = 0.15 \)), and more cancer (OR 3.09 [0.55–18.20] \( p = 0.21 \)) in the group with large vessel involvement (Fig. 4B). There was no major difference in treatment, consisting mainly of corticosteroids (100 versus 93%), cyclophosphamide (40 versus 54%), and rituximab (20 versus 15%). Relapse was slightly more common in the LVV group (OR 3.68 [0.57–45.88] \( p = 0.37 \)).

PET-CT was performed in 12 of the 101 patients and positive for LVV in one case (patient 1). However, most patients (74/101) had an injected thoracic CT-scan which makes it possible to detect vasculitis of the large vessels by wall thickening and uptake of contrast medium of the arterial wall. Of the remaining patients, 12 of the 27 patients had a cardiac ultrasound. Three temporal artery biopsies were performed when typical clinical symptoms of temporal arteritis were present (2/3 positive). In one case, histological examination was performed following aortic replacement (patient 5).

**Discussion**

The overlap between LVV and AAV is rare. Nevertheless, we found a prevalence of 5.0% [95% CI 1.6–11.2%] in our cohort of 101 patients. Beside several case reports, there
is little systematic data available. Nishino et al. reported five cases of temporal arteritis in a cohort of 345 patients with GPA, corresponding to a prevalence of only 1.4% [4]. Conversely, a more recent French retrospective study analyzed 120 patients with a diagnosis of GCA and identified 7 patients (5.8%) with necrotizing vasculitis, polyarteritis nodosa in two cases, one GPA, three MPA and an unclassified systemic vasculitis [7]. Furthermore, Delaval et al. recently described 50 cases of temporal arteritis with features of AAV as compared to controls with classic GCA in a retrospective case–control study [26]. Atypical symptoms for GCA with ENT involvement was present in 32% of the patients, followed by renal (26%), pulmonary (20%) and neurologic (16%) involvement. Moreover, fibrinoid necrosis and small branch vasculitis was found in 23% of these patients but in none of the controls with classic GCA. The authors, therefore, proposed to actively search for AAV in patients suffering from temporal arteritis with atypical clinical symptoms, a suggestive histology (fibrinoid necrosis), or resistance to treatment. A review of the literature published in 2018 searching for case reports of GPA with concomitant cephalic GCA (e.g., temporal arteritis), reported a total of 15 cases [8]. Unfortunately, the data were heterogeneous, unlike our study, not all patients had ANCA blood testing. In addition, not all patients had biopsies compatible with both entities. Interestingly, in seven cases, GCA preceded GPA while in three cases GPA was diagnosed before GCA. Four patients had GPA and GCA concomitantly. In our study, two patients had GPA before GCA (with aortitis), and three had GPA and GCA concurrently (with temporal arteritis).

Skeik N et al. report ten cases of aortitis related to AAV, in addition to their case report, and suggested using rituximab for treatment [27]. By studying 16 consecutive patients with periaortitis diagnosed by CT scanning, Vaglio et al.
identified three cases with positive ANCA including one with crescentic necrotizing glomerulonephritis [28]. Finally, 16 GPA patients with aortitis, aortic dissection and/or aneurysm were reported in a recent study from China [29]. The prevalence of LVV in our study was significantly higher than that of the southern German population. However, it is important to emphasize that this hospital-based prevalence is not directly comparable to a population-based prevalence.

The pathophysiologic mechanisms of large vessels involvement in AAV are largely unknown. While some authors speculate on invasive inflammatory cells and granulomas causing aortitis, others believe that inflammation results from necrotizing vasculitis involving the vasa vasorum of the aortic wall (like in Takayasu disease) [30]. But the most intriguing question is whether large vessel involvement in AAV is a coincidental overlap of AAV–GCA/AAV–Takayasu disease or whether LVV belongs to the spectrum of AAV. Chirinos JA et al. support the second hypothesis based on a review of the literature with clear epidemiologic, clinical and pathologic differences between large-vessel AAV on one side and GCA/Takayasu on the other side [31]. However, this point remains a matter of debate.

Analysis of the demographic data of AAV patients with large-vessel involvement does not show any clear differences. ENT manifestations seemed to be more common, not surprisingly since all cases with LVV were identified among patients with GPA. Investigation of cardiovascular risk factors revealed a trend towards a higher prevalence of hypertension, dyslipidemia, and tobacco in the LVV group. Moreover, we found more cardiovascular disease of any type (hypertensive, valvular, rhythmic, ischemic, dilated or constrictive) in the LVV group (OR 6.37 [0.97–79.13] p = 0.15). This could be explained either by a link between GCA and cardiovascular risk factors, there was no age difference.

Table 2  Demographic and clinical characteristics of the ANCA-associated vasculitis patients with large vessel vasculitis involvement (next page)

| Characteristics          | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 |
|--------------------------|-----------|-----------|-----------|-----------|-----------|
| Demography               |           |           |           |           |           |
| Age at diagnosis (years)  | 66        | 52        | 76        | 63        | 46        |
| Sex                      | F         | F         | F         | M         | F         |
| Diagnosis                | GPA       | GPA       | GPA       | GPA       | GPA       |
| ANCA associated vasculitis|           |           |           |           |           |
| Large-vessels vasculitis  | Aortitis  | Temporal arteritis | Temporal arteritis | Temporal arteritis | Aortitis  |
| Clinical manifestations   |           |           |           |           |           |
| ENT                      | Sinusitis, SMO | Sinusitis | NCD, SGS | Crusts, OPT | Nasal polyps |
| Renal                    | –         | Hematuria | –         | –         | –         |
| Pulmonary                | Nodules/infiltrate | –     | Nodules   | Nodule   | –         |
| Neurologic               | –         | Pachymeningitis | –      | –         | –         |
| Joints                   | Arthritis | –         | –         | –         | –         |
| Cardiovascular risk factors |          | Hypertension, tobacco | Dyslipidemia, tobacco, DM | Hypertension, tobacco | Hypertension, tobacco |
| Laboratory               |           |           |           |           |           |
| ANCA                     | cANCA-PR3 | cANCA-PR3 | pANCA-MPO | cANCA-PR3 | cANCA-PR3 |
| Creatinin at diagnosis (mmol/l) | –       | 42        | 59        | –         | –         |
| CRP at diagnosis (mg/l)   | –         | 176       | 120       | –         | –         |
| Sedimentation rate at diagnosis (mm/l) | –     | 85        | 67        | –         | –         |
| Histology                | Nasal(–) | Nasal(–), TA(+) | Renal(+), TA(+) | TA(–)* | Eye(+) Aorta(+) |
| Treatments               |           |           |           |           |           |
| Induction                | Cs+Cp     | Cs+Rtx   | Cs + Mtx  | Cs + Mtx  | Cs+Cp     |
| Relapse                  | Cs + Rtx  | –         | –         | –         | Cs + Rtx  |

M male, F female, GPA granulomatosis with polyangiitis, SMO sero-mucous otitis, NCD nasal cartilage destruction, SGS subglottic stenosis, OPT orbit pseudotumor, DM diabetes mellitus, DL dyslipidemia, TA temporal artery, Rtx rituximab, Cs corticosteroids, Mtx methotrexate, Cp cyclophosphamide

*Typical symptoms with jaw claudication, hyperesthesia of the scalp and pains of the belts
The trend for a higher slightly higher prevalence of cancers (3.09 [0.55–18.20] p = 0.21) can also not be explained by age. Finally, we note that LVV patients have slightly more relapse. Unfortunately, our study did not have the statistical power to detect statistically significant differences between the groups with and without involvement of the large vessels. Thus, it is difficult to draw firm conclusions and studies with more cases are needed to corroborate our results.

Our study has some limitations. First to mention is the small overall number of AAV patients with LVV which causes a significant risk of analysis bias. Second, the group of LVV patients is not homogeneous. We have no explanation why we did not identify any LVV patients associated to MPA or EGPA, even though several such cases are described in the literature [2, 7, 14–19]. Third, not all patients had the same diagnostic approach using different methods of investigation. Patient 1 was diagnosed with LVV based on PET-CT imaging results, while in patients 2, 3 and 5, LVV diagnosis was based on biopsy samples, and in patient 4 a diagnosis of GCA was made based on ACR criteria. However, the
diagnostic approach for LVV is currently changing with an increasing role of imaging studies and a diminished role of biopsy studies. Hence, increasing use of imaging studies may explain the increase in LVV prevalence. Finally, only approximately 70% of the patients underwent large vessels imaging. Consequently, LVV might not have been detected in some of the remaining patients potentially underestimating, therefore, the overall prevalence.

It remains controversial to systematically recommend large vessel evaluation in all AAV patients. Nevertheless, proactive history taking and careful physical examination for signs or symptoms suggestive of LVV are required. Furthermore, considering the presence of LVV in approximately 1 out of 20 patients with AAV and the potential morbidity associated with aneurysms for instance, it seems reasonable to evaluate existing imaging studies (US, MRI, CT scans, echocardiography) or to request additional investigations in the search for LVV. However, this question needs to be addressed in a large multi-center study.

**Conclusion**

Large-vessels involvement was found in five AAV patients (two with aortitis and three with temporal arteritis) in our cohort of 101 patients with GPA, EGPA, MPA, resulting in a hospital-based prevalence of 5.0%. According to the clinical importance of this co-existing diseases, evaluation for LVV may be considered systematically in the future diagnostic workup of AAV.

**Acknowledgements** Foundation Henriette Meyer.

**Funding** Open Access funding provided by Université de Genève.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Jc J, Rj F, Pa B et al (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–11. https://doi.org/10.1002/Art.37715
2. Leavitt RY, Fauci AS (1986) Polyangiitis overlap syndrome. Classification and prospective clinical experience. Am J Med 81(1):79–85
3. Ong Tone S, Godra A, Ing E (2013) polyangiitis overlap syndrome with granulomatosis with polyangiitis (Wegener’s) and giant cell arteritis. Can J Ophthalmol 48(1):E6-8. https://doi.org/10.1016/J.Jcjo.2012.08.018
4. Nishino H, Deremee RA, Rubino FA, Parisi IE (1993) Wegener’s granulomatosis associated with vasculitis of the temporal artery: report of five cases. Mayo Clin Proc 68(2):115–21
5. Mccarthy A, Farrell M, Hedley-Whyte T et al (2013) Granulomatosis with polyangiitis masquerading as giant cell arteritis. J Neurol 260(6):1661–1663. https://doi.org/10.1007/S00415-013-6913-3
6. Small P, Brisson ML (1991) Wegener’s granulomatosis presenting as temporal arteritis. Arthritis Rheum 34(2):220–3
7. Hamidou MA, Moreau A, Toquet C, El Kouri D, De Faucaul P, Grolleau JY (2003) Temporal arteritis associated with systemic necrotizing vasculitis. J Rheumatol 30(10):2165–9
21. Gil H, Mauny F, Meaux-Ruault N et al (2008) Usefulness of anti-neutrophil cytoplasmic antibodies in giant cell arteritis. Rev Med Interne 29(10):780–784. https://doi.org/10.1016/J.Revmed.2008.01.011

22. Bossuyt X, Cohen Tervaert JW, Arimura Y et al (2017) Position paper: revised 2017 international consensus on testing of Ancas in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 13(11):683–92. https://doi.org/10.1038/Nrrheum.2017.140

23. At M, Gg H, Jt L et al (1990) The American college of rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angitis). Arthritis Rheum 33(8):1094–1100

24. Gg H, Da B, Ba M et al (1990) The American college of rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33(8):1122–1128

25. Reinhold-Keller E, Zeidler A, Gutfeisch J, Peter HH, Raspe HH, Gross WL (2000) Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) 39(12):1396–402. https://doi.org/10.1093/Rheumatology/39.12.1396

26. Delaval L, Samson M, Schein F et al (2020) Temporal arteritis revealing antineutrophil cytoplasmic antibody-associated vasculitides: a case-control study. Arthritis Rheumatol. https://doi.org/10.1002/Art.41527

27. Skeik N, Hari G, Nasr R (2019) Aortitis caused by antineutrophil cytoplasmic antibodies (Anca)-associated vasculitides: a case-based review. Rheumatol Int 39(11):1983–1988. https://doi.org/10.1007/S00029-019-04343-3

28. Vaglio A, Corradi D, Manenti L, Ferretti S, Garini G, Buzio C (2003) Evidence of autoimmunity in chronic periaortitis: a prospective study. Am J Med 114(6):454–462. https://doi.org/10.1016/S00296-019(03)0056-1

29. Pan L, Yan JH, Gao FQ et al (2019) Case report of a 28-year-old man with aortic dissection and pulmonary shadow due to granulomatosis with polyangiitis. BMC Pulm Med 19(1):2252–4

30. Zuckerman R, Patel M, Alpert DR (2017) A tale of two vasculitides: biopsy-proven giant cell arteritis followed by the independent development of renal-limited microscopic polyangiitis. BMJ Case Rep. https://doi.org/10.1136/Bcr-2017-219228

31. Konishi M, Koarada S, Yamaguchi K et al (2011) Temporal artery involvement in microscopic polyangiitis. Intern Med 50(9):1033–1037

32. Albreiki D, Al Belushi F, Patel V, Farmer J (2016) When a temporal artery biopsy reveals a diagnosis other than temporal arteritis: eosinophilic granulomatosis with polyangiitis. Can J Ophthalmol 51(3):E108–E109. https://doi.org/10.1016/J.Cjo.2016.01.014

33. Morinaga A, Ono K, Komai K, Yamada M (2007) Microscopic polyangiitis presenting with temporal arteritis and multiple cranial neuropathies. J Neurol Sci 256(1–2):81–83. https://doi.org/10.1016/J.Jns.2007.01.009

34. Fujii K, Tsutsumi T, Takaoka K, Osugi Y, Ando S, Koyama Y (2012) A Concomitant case of giant cell arteritis and microscopic polyangiitis with hemoperitoneum by rupture of the gastroepiploic artery. Mod Rheumatol 22(6):934–938. https://doi.org/10.1007/S10165-012-0610-4

35. Marini F, Fontana A, Russo S, Citerio G, Nucera MC et al (2008) Giant cell arteritis mimicking temporal arteritis. Rev Med Interne 29(10):830–831. https://doi.org/10.1016/J.Revmed.2008.01.010

36. Pan L, Yan JH, Gao FQ et al (2019) Case report of a 28-year-old man with aortic dissection and pulmonary shadow due to granulomatosis with polyangiitis. BMC Pulm Med 19(1):2252–4

37. Konishi M, Koarada S, Yamaguchi K et al (2011) Case of microscopic polyangiitis and giant cell arteritis after influenza vaccination. Nihon Rinsho Meneki Gakkai Kaishi 34(3):154–161

38. Albreiki D, Al Belushi F, Patel V, Farmer J (2016) When a temporal artery biopsy reveals a diagnosis other than temporal arteritis: eosinophilic granulomatosis with polyangiitis. Can J Ophthalmol 51(3):E108–E109. https://doi.org/10.1016/J.Cjo.2016.01.014

39. Berthelot JM, Lamour A, Mottier D et al (1992) Anti-neutrophil cytoplasm antibodies in patients with giant cell arteritis and/or polynymalgia rheumatica. Ann Med Interne (Paris) 143(7):429–32

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.